Winthrop-University Hospital was the first medical institution in the New York Metropolitan region — and is among a select group in the country — to offer breakthrough CyberKnife® radiosurgery, providing new hope to thousands of people with tumors and lesions once considered inoperable.
Winthrop’s CyberKnife® team, among the most experienced in the world, was recently acknowledged at the International CyberKnife® Meeting by Accuray as having the second largest experience worldwide in treating prostate cancer patients with CyberKnife.
With high-tech, cruise-missile-guidance technology and ultra-flexible, computer-controlled robotics, CyberKnife® delivers extraordinarily accurate, precisely targeted radiation to tumors throughout the body when radiation therapy is indicated. The beams can be sculpted to reach small, deeply imbedded, complex masses, minimizing damage to healthy tissue.
CyberKnife® is non-invasive and has transformed radiosurgeries of the brain, spine and soft-tissue (lungs, liver, pancreas and kidneys) into painless, bloodless outpatient procedures that permit patients to undergo treatment and usually resume normal activities soon after the procedure.
The Center’s multidisciplinary team, which collaborates to develop and implement comprehensive treatment plans tailored to individual needs, includes:
Primary and Metastatic Brain Tumors
Spinal Cord Tumors
Soft Tissue Tumors
Skull Base Tumors
Recurrent and Residual Tumors
Arteriovenous Malformations (AVMs)
Functional Disorders, such as Trigeminal Neuralgia
The CyberKnife® Advantage
Treatment for tumors inoperable by conventional surgery or other stereotactic radiosurgery
Additional treatment option for tumors that have received maximum allowed radiation
Painless, bloodless and non-invasive
High-dose radiation delivered accurately
Ability to treat multiple tumors at different locations during a single session
Healthy tissue unharmed
No need for invasive, uncomfortable head frame or skull pins
Full-body treatment capability
CyberKnife® is cleared by the FDA for treatment of tumors and lesions anywhere in the body when radiation therapy is indicated. However, patients should consult their physicians to determine if this treatment approach is right for them.